Using laser therapy to prevent mouth sores in cancer patients undergoing stem cell transplants
Laser Photobiomodulation to Prevent Oral Mucositis and Functional Impairment Among Adult Hematologic Cancer Patients Undergoing Hematopoietic Stem Cell Transplantation
This study is testing if daily laser treatment can help prevent mouth sores in adults with blood cancers who are getting stem cell transplants.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Universidad del Desarrollo Academic / other |
| Locations | 1 site (Santiago, Santiago Metropolitan) |
| Trial ID | NCT06260111 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of laser photobiomodulation in preventing oral mucositis and functional impairments in adult patients with hematologic cancers undergoing hematopoietic stem cell transplantation (HSCT). Participants will receive daily laser treatment in their oral cavity from the first day of transplantation conditioning until three days post-transplant. The study will compare the outcomes of those receiving laser therapy to a control group receiving standard care. Primary outcomes include the incidence of oral mucositis, functional capacity, and patient acceptability of the treatment.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 65 with hematologic neoplasms who are scheduled for HSCT and can understand Spanish.
Not a fit: Patients with cognitive deficits, clinical instability, or pre-existing oral infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly reduce the incidence of oral mucositis and improve recovery outcomes for patients undergoing HSCT.
How similar studies have performed: While few experimental trials have evaluated photobiomodulation for oral mucositis, this approach is relatively novel in the context of HSCT.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults over 18 years of age with hematological neoplasms who require medical indication of an HSCT according to the Transplant Committee at Clinica Dávila * With sufficient understanding of Spanish. Exclusion Criteria: * Observed cognitive deficit * Patients who do not meet the criteria of clinical stability, progression of the disease, and that do not fulfill requirement of the National Hematopoietic Stem Cell Transplantation Program. * Participants with an oral infection from any type of Candida prior to HSCT.
Where this trial is running
Santiago, Santiago Metropolitan
- Clinica Dávila — Santiago, Santiago Metropolitan, Chile (Recruiting)
Study contacts
- Principal investigator: Cinara Sacomori, Ph.D. — Universidad del Desarrollo
- Study coordinator: Cinara Sacomori, Ph.D.
- Email: csacomori@udd.cl
- Phone: +562 23279661
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.